{"id":"W4387812143","doi":"10.1016/j.annonc.2023.09.1341","title":"2314P Quality and safety of research biopsies (RB) in oncology clinical trials","year":2023,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Radiomics and Machine Learning in Medical Imaging","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"ca_institutions":"","funders":"Cilag; HORIZON EUROPE Framework Programme; Chugai Pharmaceutical; AstraZeneca; Genentech; INCLIVA Instituto de Investigación Sanitaria; Sun Pharma; EMD Serono; Mersana Therapeutics; Deutschen Konsortium für Translationale Krebsforschung; Incyte; Servier; Sociedad Española de Oncología Médica; Cancer Research UK; Seagen; Grifols; Fundación Científica Asociación Española Contra el Cáncer; MacroGenics; American Society of Clinical Oncology; Oncode Institute; Eisai Canada; BeiGene; Mirati Therapeutics; Amgen; Astellas Pharma; Deciphera Pharmaceuticals; Daiichi Sankyo Europe; Takeda Oncology; European Society for Medical Oncology; Agios Pharmaceuticals; Clovis Oncology; Les Laboratories Pierre Fabre; Novocure; Regeneron Pharmaceuticals; Ipsen; Takeda Pharmaceuticals International; Array BioPharma; Taiho Pharmaceutical; Merck KGaA; Samsung; Eisai; FibroGen; Bristol-Myers Squibb; Eli Lilly and Company; F. Hoffmann-La Roche; Loxo Oncology; European Association for Cancer Research; Pharmacyclics; Exelixis; Sanofi; PharmaMar; Novartis Farmacéutica; OncoMed Pharmaceutical; Pfizer; Celgene","keywords":"Medicine; Clinical trial; Context (archaeology); Internal medicine; Breast cancer; Oncology; Cancer; Surgery","routes":{"ca_aff":false,"ca_fund":true,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":true},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.06185869,0.0004130083,0.001626908,0.001026881,0.0005323587,0.003183192,0.001048664,0.002405213,0.00983878],"category_scores_gemma":[0.2444215,0.000573568,0.002381803,0.002120476,0.002080359,0.003004771,0.001528033,0.002755808,0.001623623],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.001933,"about_ca_system_score_gemma":0.002038751,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001434278,"about_ca_topic_score_gemma":0.00119939,"domain_scores_codex":[0.9238231,0.05941931,0.004811938,0.004227408,0.006634752,0.001083499],"domain_scores_gemma":[0.6987856,0.2116829,0.04965316,0.01957006,0.0166346,0.00367376],"domain_codex":null,"domain_gemma":"methods","domain_candidate":"methods","domain_consensus":null,"study_design_codex":"design_other","study_design_gemma":"observational","study_design_scores_codex":[0.1395458,0.0005111236,0.3112124,0.005611462,0.01619164,0.0004826289,0.0006499283,0.01177295,0.003744006,0.008737721,0.02277111,0.4787692],"study_design_scores_gemma":[0.02096156,0.03613045,0.723221,0.004084616,0.02245889,0.004791824,0.0007650571,0.02657949,0.01497337,0.05968016,0.08602464,0.0003289183],"study_design_candidate":"observational","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.7044776,0.1362833,0.05032659,0.03791131,0.002760695,0.00144571,0.01537155,0.0008711343,0.05055208],"genre_scores_gemma":[0.9874551,0.00276208,0.00374766,0.002331157,0.0005343469,0.0002447954,0.001384101,0.0001522633,0.001388516],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.9381413,"threshold_uncertainty_score":0.3271439,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.6642324169962353,"score_gpt":0.6911398944728597,"score_spread":0.02690747747662448,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}